Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study of its Category 1 chemical drug KC1036. The study will assess the efficacy and safety of KC1036 in combination with docetaxel for the treatment of advanced non-driver-gene lung adenocarcinoma in patients who have previously failed platinum-containing chemotherapy and PD-1/PD-L1 antibody treatment.
KC1036: Mechanism and Clinical Progress
KC1036 is a small molecule cancer therapy targeting AXL, VEGFR2, and FLT3. The drug received clinical trial approval in China in January 2020. A Phase I clinical study has demonstrated that KC1036 has a favorable safety and tolerability profile, along with promising preliminary anti-tumor efficacy in multiple advanced solid tumors. As of the announcement date, over 100 patients with various advanced solid tumors have been enrolled in multiple studies, where KC1036 has shown good clinical safety and efficacy.
Expanded Clinical Development
In addition to the newly approved Phase II trial for advanced non-driver-gene lung adenocarcinoma, KC1036 also received approval earlier this week to enter a separate Phase II trial for the assessment of advanced thymoma and thymic carcinoma. These expanded trials underscore Konruns’ commitment to exploring the therapeutic potential of KC1036 across multiple cancer indications, positioning the drug as a potential new treatment option for patients with significant unmet needs.
Future Outlook
The advancement of KC1036 into Phase II clinical studies highlights Konruns Pharmaceutical’s dedication to developing innovative cancer therapies. With a robust clinical program and demonstrated safety and efficacy profiles, KC1036 is poised to make a meaningful impact on patient outcomes in advanced solid tumors. Konruns’ ongoing efforts to expand the drug’s clinical applications further solidify its position in the oncology space.-Fineline Info & Tech
